Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on adolescent vaping

LIVE: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?
ADVANCED SEARCH
Log in
Top
Cardiology and Therapy

Open Access 23-12-2024 | Atrial Fibrillation | Review

Atrial Fibrillation in Patients with Breast Cancer: A Literature Review

Authors: Mozidat Olamide Bello, Mark Wadid, Aishwarya Malode, Vahin Patel, Anuj Shah, Ankit Vyas, Hassaan Ali Ahmad, Tushar Tarun, Sourbha Dani, Javaria Ahmad, Corrine Zarwan, Sarju Ganatra

Published in: Cardiology and Therapy

Login to get access

Abstract

In addition to traditional risk factors, patients with breast cancer are at an increased risk of atrial fibrillation due to cancer itself and certain cancer therapies. Atrial fibrillation in these patients adds to their morbidity and mortality. The precise mechanisms leading to the increased atrial fibrillation in patients with breast cancer are not well understood. The main goal of atrial fibrillation management in this population is to facilitate uninterrupted cancer treatment while addressing the arrhythmia and other cardiovascular sequelae of cancer treatment. Rhythm control is often challenging to implement in patients with breast cancer during active antineoplastic therapy because of the need for uninterrupted anticoagulation, potential drug–drug interactions between cancer treatments and antiarrhythmic medications, and the increased likelihood of atrial fibrillation recurrence. Prevention of thromboembolism and anticoagulation can also be challenging in patients with breast cancer as a result of the increased risk of cancer-related procoagulant state and coagulopathies. The integration of a cardio-oncology team and a multidisciplinary approach are crucial for better outcomes. The therapeutic interventions should be tailored toward individual patients’ profiles through a shared decision-making approach. The precise mechanisms leading to the increased atrial fibrillation in patients with breast cancer are not well understood, highlighting the gaps in our knowledge. More research is required to reduce these gaps, refine risk stratification, and optimize treatment strategies in these patients.
Literature
1.
Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) study. JAMA. 2001;285(18):2370.PubMedCrossRef
2.
Kattelus H, Kesäniemi YA, Huikuri H, Ukkola O. Cancer increases the risk of atrial fibrillation during long-term follow-up (OPERA study). PLoS ONE. 2018;13(10):e0205454.PubMedPubMedCentralCrossRef
3.
4.
5.
D’Souza M, Smedegaard L, Madelaire C, et al. Incidence of atrial fibrillation in conjunction with breast cancer. Heart Rhythm. 2019;16(3):343–8.PubMedCrossRef
6.
Guha A, Fradley MG, Dent SF, et al. Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis. Eur Heart J. 2022;43(4):300–12.PubMedCrossRef
7.
Rhea I, Burgos PH, Fradley MG. Arrhythmogenic anticancer drugs in cardio-oncology. Cardiol Clin. 2019;37(4):459–68.PubMedCrossRef
8.
9.
Ahmad J, Thurlapati A, Thotamgari S, et al. Anti-cancer drugs associated atrial fibrillation—an analysis of real-world pharmacovigilance data. Front Cardiovasc Med. 2022;9:739044.PubMedPubMedCentralCrossRef
10.
Yao X, Hu Q, Liu X, et al. Atrial fibrillation and breast cancer-vicious twins? A systematic review and meta-analysis. Front Cardiovasc Med. 2023;10:1113231.PubMedPubMedCentralCrossRef
11.
Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol. 2014;63(10):945–53.PubMedCrossRef
12.
13.
Madnick DL, Fradley MG. Atrial fibrillation and cancer patients: mechanisms and management. Curr Cardiol Rep. 2022;24(10):1517–27.PubMedCrossRef
14.
Menichelli D, Vicario T, Ameri P, et al. Cancer and atrial fibrillation: epidemiology, mechanisms, and anticoagulation treatment. Prog Cardiovasc Dis. 2021;66:28–36.PubMedCrossRef
15.
Chu G, Versteeg HH, Verschoor AJ, et al. Atrial fibrillation and cancer—an unexplored field in cardiovascular oncology. Blood Rev. 2019;35:59–67.PubMedCrossRef
16.
17.
Semeraro GC, Meroni CA, Cipolla CM, Cardinale DM. Atrial fibrillation after lung cancer surgery: prediction, prevention and anticoagulation management. Cancers (Basel). 2021;13(16):4012.PubMedCrossRef
18.
Zhang L, Li X, Wu H, Luo J. Risk factors associated with atrial fibrillation following lung cancer surgery: a multi-center case-control study. Asian J Surg. 2024;47(1):176–83.PubMedCrossRef
19.
20.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials. Lancet. 2023;401(10384):1277–92.
21.
Geyer CE, Blum JL, Yothers G, et al. Long-term follow-up of the anthracyclines in early breast cancer trials (USOR 06–090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology]). JCO. 2024;42(12):1344–9.CrossRef
22.
Ho I, Wong CK, Wong YK, et al. Aromatase inhibitor therapy increases the risk of new-onset atrial fibrillation in patients with breast cancer. JACC Asia. 2024;4(2):150–60.PubMedCrossRef
23.
Yu KD, Ye FG, He M, et al. Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2020;6(9):1390.PubMedCrossRef
24.
25.
Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–801.PubMedCrossRef
26.
Font J, Milliez P, Ouazar AB, Klok FA, Alexandre J. Atrial fibrillation, cancer and anticancer drugs. Arch Cardiovasc Dis. 2023;116(4):219–26.PubMedCrossRef
27.
Burashnikov A. Atrial fibrillation induced by anticancer drugs and underling mechanisms. J Cardiovasc Pharmacol. 2022;80(4):540–6.PubMedCrossRef
28.
Yuan M, Tse G, Zhang Z, et al. The incidence of atrial fibrillation with trastuzumab treatment: a systematic review and meta-analysis. Cardiovasc Ther. 2018;36(6):e12475.PubMedCrossRef
29.
Wu WC, Huang CC, Tsai YF, et al. The association of trastuzumab with atrial fibrillation and heart failure in breast cancer patients in routine clinical practice: a population-based propensity score matching and competing risk model analysis. Breast Cancer Res Treat. 2023;198(1):113–22.PubMedCrossRef
30.
Escudier M, Cautela J, Malissen N, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017;136(21):2085–7.PubMedCrossRef
31.
Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19(9):e447–58.PubMedCrossRef
32.
Recht A, Comen EA, Fine RE, et al. Postmastectomy radiotherapy: an American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology focused guideline update. J Clin Oncol. 2016;34(36):4431–42.PubMedCrossRef
33.
Jacobs JEJ, L’Hoyes W, Lauwens L, et al. Mortality and major adverse cardiac events in patients with breast cancer receiving radiotherapy: the first decade. J Am Heart Assoc. 2023;12(8):e027855.PubMedPubMedCentralCrossRef
34.
Grewal US, Patel HP, Sheth AR, Beedupalli K, Dominic P. Impact of radiation on inpatient outcomes in patients with breast cancer and atrial fibrillation: a nationwide analysis. Heart Rhythm. 2022;19(7):1210–1.PubMedCrossRef
35.
Avula V, Sharma G, Kosiborod MN, et al. SGLT2 inhibitor use and risk of clinical events in patients with cancer therapy-related cardiac dysfunction. JACC Heart Fail. 2024;12(1):67–78.PubMedCrossRef
36.
37.
Carlson LE, Watt GP, Tonorezos ES, et al. Coronary artery disease in young women after radiation therapy for breast cancer: the WECARE study. JACC CardioOncol. 2021;3(3):381–92.PubMedPubMedCentralCrossRef
38.
39.
Pastori D, Menichelli D, Di Rocco A, et al. Bleeding and thrombotic events in atrial fibrillation patients with cancer: a systematic review and meta-analysis. Intern Emerg Med. 2023;18(2):655–65.PubMedCrossRef
40.
López-Fernández T, Martín-García A, Roldán Rabadán I, et al. Atrial fibrillation in active cancer patients: expert position paper and recommendations. Rev Esp Cardiol (Engl Ed). 2019;72(9):749–59.PubMedCrossRef
41.
Beavers CJ, Rodgers JE, Bagnola AJ, et al. Cardio-oncology drug interactions: a scientific statement from the American Heart Association. Circulation. 2022;145(15):e811–38.PubMedCrossRef
42.
Karlstaedt A, Barrett M, Hu R, Gammons ST, Ky B. Cardio-oncology: understanding the intersections between cardiac metabolism and cancer biology. JACC Basic Transl Sci. 2021;6(8):705–18.PubMedPubMedCentralCrossRef
43.
Pathak RK, Middeldorp ME, Meredith M, et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort. J Am Coll Cardiol. 2015;65(20):2159–69.PubMedCrossRef
44.
Chung MK, Eckhardt LL, Chen LY, et al. Lifestyle and risk factor modification for reduction of atrial fibrillation: a scientific statement from the American Heart Association. Circulation. 2020;141(16):e750–72.PubMedCrossRef
45.
46.
Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383(14):1305–16.PubMedCrossRef
47.
Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2024;149(1):e1-156.PubMedCrossRef
48.
Grouthier V, Lebrun-Vignes B, Glazer AM, et al. Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors. Heart. 2018;104(22):1859–63.PubMedCrossRef
49.
Haq IU, Akhiyat N, Anan AR, et al. Mediastinal radiation therapy for breast cancer in female patients is an independent risk factor for atrial fibrillation recurrence post-catheter ablation. J Interv Card Electrophysiol. 2022;65(3):751–6.PubMedCrossRef
50.
Thotamgari SR, Sheth AR, Patel HP, et al. Safety of catheter ablation for atrial fibrillation in patients with cancer: a nationwide cohort study. Postgrad Med. 2023;135(6):562–8.PubMedCrossRef
51.
Ganatra S, Abraham S, Kumar A, et al. Efficacy and safety of catheter ablation for atrial fibrillation in patients with history of cancer. Cardiooncology. 2023;9(1):19.PubMedPubMedCentral
52.
53.
Guan J, Zhang M. Cardiotoxicity of anthracycline-free targeted oncological therapies in HER2-positive breast cancer (review). Oncol Lett. 2020;21(2):100.PubMedPubMedCentralCrossRef
54.
Ederhy S, Di Angelantonio E, Mallat Z, et al. Levels of circulating procoagulant microparticles in nonvalvular atrial fibrillation. Am J Cardiol. 2007;100(6):989–94.PubMedCrossRef
55.
Chen ST, Hellkamp AS, Becker RC, et al. Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. Eur Heart J Qual Care Clin Outcomes. 2019;5(2):145–52.PubMedCrossRef
56.
Ajabnoor AM, Parisi R, Zghebi SS, et al. Common cancer types and risk of stroke and bleeding in patients with nonvalvular atrial fibrillation: a population-based study in England. J Am Heart Assoc. 2023;12(19):e029423.PubMedPubMedCentralCrossRef
57.
Pastori D, Marang A, Bisson A, et al. Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: a nationwide cohort study. Cancer. 2021;127(12):2122–9.PubMedCrossRef
58.
Atterman A, Friberg L, Asplund K, Engdahl J. Net benefit of oral anticoagulants in patients with atrial fibrillation and active cancer: a nationwide cohort study. Europace. 2020;22(1):58–65.PubMed
59.
Mariani MV, Magnocavallo M, Straito M, et al. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis. J Thromb Thrombolysis. 2021;51(2):419–29.PubMedCrossRef
60.
Pacholczak-Madej R, Bazan-Socha S, Zaręba L, Undas A, Dropiński J. Direct oral anticoagulants in the prevention of stroke in breast cancer patients with atrial fibrillation during adjuvant endocrine therapy: a cohort study. Int J Cardiol. 2021;1(324):78–83.CrossRef
61.
Melloni C, Dunning A, Granger CB, et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE trial. Am J Med. 2017;130(12):1440-1448.e1.PubMedCrossRef
62.
Yang P, Zhu D, Xu X, et al. Efficacy and safety of oral anticoagulants in atrial fibrillation patients with cancer—a network meta-analysis. Heart Fail Rev. 2020;25(5):823–31.PubMedCrossRef
63.
McBane RD, Wysokinski WE, Le-Rademacher JG, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost. 2020;18(2):411–21.PubMedCrossRef
64.
Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597–609.PubMedCrossRef
65.
Rose AJ, Hylek EM, Ozonoff A, Ash AS, Reisman JI, Berlowitz DR. Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). Circ Cardiovasc Qual Outcomes. 2011;4(1):22–9.PubMedCrossRef
66.
Pardo Sanz A, Rincón LM, Guedes Ramallo P, et al. Current status of anticoagulation in patients with breast cancer and atrial fibrillation. Breast. 2019;46:163–9.PubMedCrossRef
67.
Munir MB, Khan MZ, Darden D, et al. Contemporary procedural trends of Watchman percutaneous left atrial appendage occlusion in the United States. J Cardiovasc Electrophysiol. 2021;32(1):83–92.PubMedCrossRef
68.
Shabtaie SA, Tan NY, Ward RC, et al. Left atrial appendage occlusion in patients with atrial fibrillation and cancer. JACC CardioOncol. 2023;5(2):203–12.PubMedPubMedCentralCrossRef
69.
Agarwal S, Guha A, Munir MB, DeSimone CV, Deshmukh A, Asad ZUA. Outcomes of patients with cancer undergoing percutaneous left atrial appendage occlusion. J Interv Card Electrophysiol. 2023;66(8):1791–4.PubMedCrossRef
70.
Zhang Y, Yang Z, Almani MU, Soon-Shiong R, Liu B. Utilization and short-term outcomes of percutaneous left atrial appendage occlusion in patients with cancer. Cardiooncology. 2023;9(1):39.PubMedPubMedCentral
71.
Bagga S, Dani SS, Hook BG, Nohria A, Ganatra S. Strategies to balance stroke and bleeding risk in patients with atrial fibrillation and cancer. Heart Rhythm. 2021;18(9):1533–8.PubMedCrossRef
72.
Ahmad J, Muthyala A, Kumar A, Dani SS, Ganatra S. Disparities in cardio-oncology: effects on outcomes and opportunities for improvement. Curr Cardiol Rep. 2022;24(9):1117–27.PubMedPubMedCentralCrossRef
73.
Ganatra S, Dani SS, Kumar A, et al. Impact of social vulnerability on comorbid cancer and cardiovascular disease mortality in the United States. JACC CardioOncol. 2022;4(3):326–37.PubMedPubMedCentralCrossRef
74.
Samuelson Bannow BR, Lee AYY, Khorana AA, et al. Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: a systematic review. Res Pract Thromb Haemost. 2018;2(4):664–9.PubMedPubMedCentralCrossRef
75.
Pastori D, Marang A, Bisson A, Herbert J, Lip GYH, Fauchier L. Performance of the HAS-BLED, ORBIT, and ATRIA bleeding risk scores on a cohort of 399 344 hospitalized patients with atrial fibrillation and cancer: data from the French National Hospital Discharge Database. J Am Heart Assoc. 2022;11(23):e026388.PubMedPubMedCentralCrossRef
76.
Abu-Qaoud MR, Kumar A, Tarun T, et al. Impact of SGLT2 inhibitors on AF recurrence after catheter ablation in patients with type 2 diabetes. JACC Clin Electrophysiol. 2023;9(10):2109–18.PubMedCrossRef
77.
Herrmann J, Lenihan D, Armenian S, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43(4):280–99.PubMedCrossRef
78.
Shen H, Rillamas-Sun E, Iribarren C, et al. Abstract 5303: Cardiovascular disease risk associated with breast cancer chemotherapy drugs: the Pathways Heart Study. Cancer Res. 2022;82(12_Supplement):5303–5303.CrossRef
79.
Nilsson G, Holmberg L, Garmo H, Terent A, Blomqvist C. Radiation to supraclavicular and internal mammary lymph nodes in breast cancer increases the risk of stroke. Br J Cancer. 2009;100(5):811–6.PubMedPubMedCentralCrossRef
80.
Zur M, Shai A, Leviov M, et al. Short-term complications of intra-operative radiotherapy for early breast cancer. J Surg Oncol. 2016;113(4):370–3.PubMedCrossRef
Metadata
Title
Atrial Fibrillation in Patients with Breast Cancer: A Literature Review
Authors
Mozidat Olamide Bello
Mark Wadid
Aishwarya Malode
Vahin Patel
Anuj Shah
Ankit Vyas
Hassaan Ali Ahmad
Tushar Tarun
Sourbha Dani
Javaria Ahmad
Corrine Zarwan
Sarju Ganatra
Publication date
23-12-2024
Publisher
Springer Healthcare
Published in
Cardiology and Therapy
Print ISSN: 2193-8261
Electronic ISSN: 2193-6544
DOI
https://doi.org/10.1007/s40119-024-00394-1

Keynote webinar | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

Keynote webinar | Spotlight on medication adherence

  • Webinar | 27-06-2024 | 18:00 (CEST)

Medication non-adherence is a major barrier to effective healthcare delivery; half of all patients do not follow their doctor’s recommendations or treatment plan.

Our experts explain the fundamentals with a practical discussion of how to manage non-adherence in two common scenarios: hypertension and asthma control.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Watch now
Image Credits